公开(公告)号：US08143274B2

公开(公告)日：2012-03-27

申请号：US10588611

申请日：2005-02-07

申请人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

发明人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

IPC分类号： C07D217/24 ,  A61K31/47

CPC分类号： C07D217/24

摘要： The present invention provides: a compound represented by the following formula (I): [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 represents —NR1R2, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; R1 represents a hydrogen atom, or a C1-8 alkyl group that may be substituted; and R2 represents a C1-8 alkyl group that is substituted with one or more substituents, —COOR3, —COR4, —COSR5, —CONR6R7, —NR22R23, or —C═NR24R25; or R1 and R2, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.

摘要翻译： 本发明提供：由下式（I）表示的化合物：[其中Y 1和Y 4表示氢原子或卤素原子; Y2和Y3中的任一个表示-NR1R2，另一个表示氢原子或卤素原子; X表示可被取代的芳基或杂芳基; R1表示氢原子或可被取代的C1-8烷基; 并且R 2表示被一个或多个取代基-COOR 3，-COR 4，-COSR 5，-CONR 6 R 7，-NR 22 R 23或-C≡NR24 R 25取代的C 1-8烷基; 或R 1和R 2与它们所键合的氮原子一起可以形成含有至少一个氮原子的4至10元杂环（其中杂环可以被一个或多个选自C组的取代基取代 ）]，其前药，或其药学上可接受的盐; 以及包含该化合物的药物，药物组合物等。

公开(公告)号：US20070185160A1

公开(公告)日：2007-08-09

申请号：US10588611

申请日：2005-02-07

申请人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

发明人： Kazuo Hattori ,  Satoshi Niizuma ,  Takehiro Okada ,  Hiroyuki Eda ,  Kenji Tatsuno ,  Miyuki Yoshida

IPC分类号： A61K31/47 ,  C07D217/24 ,  C07D401/02

CPC分类号： C07D217/24

摘要： The present invention provides: a compound represented by the following formula (I): [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 represents —NR1R2, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; R1 represents a hydrogen atom, or a C1-8 alkyl group that may be substituted; and R2 represents a C1-8 alkyl group that is substituted with one or more substituents, —COOR3, —COR4, —COSR5, —CONR6R7, —NR22R23, or —C═NR24R25; or R1 and R2, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.

摘要翻译： 本发明提供：由下式（I）表示的化合物：[其中Y 1和Y 4表示氢原子或卤素原子; Y 2和Y 3中的任一个表示-NR 1 R 2 O 2，另一个表示氢原子 或卤素原子; X表示可被取代的芳基或杂芳基; R 1表示可以被取代的氢原子或C 1-8烷基; 和R 2表示被一个或多个取代基取代的C 1-8烷基，-COOR 3，-COR 2， 4，-COSR 5，-CONR 6，R 7，-NR 22 R SUP > 23 或-C-NR 24 R 25; 或R 1和R 2与它们所键合的氮原子一起可以形成含有至少一个氮原子的4至10元杂环（ 其中所述杂环可以被一个或多个选自组C）的取代基取代，其前药或其药学上可接受的盐; 以及包含该化合物的药物，药物组合物等。